Early improvement in type 2 diabetes in obese patients following gastric bypass and bilio-pancreatic diversion: The role of the entero-insular axis;Traitement précoce du diabète de type 2 chez l'obèse après gastric bypass et diversion bilio-pancréatique: Rôle de l'axe entéro-insulinique

Journal de Chirurgie

Volumn 145, Issue 6, 2008, Pages 549-555

  Lifante, J C ^a,b   Inabnet, W B ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Bilio pancreatic diversion; Entero insular axis; GLP 1; Gut peptides; Incretin; Obesity; Type 2 diabetes

Indexed keywords

EID: 58149518735     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(08)74685-4     Document Type: Short Survey

References (50)

1. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-352.
2. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237:751-756.
3. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467-472.
4. Scopinaro N, Adami GF, marinari GM, et al. Bilio pancreatic diversion. World J Surg 1998;22:936-946.
5. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947-954.
6. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A systematic review and meta-analysis. JAMA 2004;292:1724-1737.
7. DeMaria EJ, Sugerman HJ, Kellum JM, Meador JG, Wolfe LG. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002;235:640-645.
8. Noya G, Cossu ML, Coppola M, et al. Biliopancreatic diversion preserving the stomach and pylorus in the treatment of hypercholesterolemia and diabetes type II: results in the first 10 cases. Obes Surg 1998;8:67-72.
9. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969;123:261-266.
10. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85.
11. Drucker DJ. The role of gut hormon in glucose homeostasis. J Clin Invest 2007;117:24-32.
12. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for devilopment of new obesity-diabetes drugs? Diabetes Vasc Dis Res 2007;4:150-152.
13. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptopic signaling by glucose-dependent insulinotropic polypeptidein beta(INS-1)-cells. J Endocrinol 2002;174:233-246.
14. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 Amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-307.
15. Elahi D, McAloon-Dyke M, Fukagawa, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjecs. Regul Pept 1994;51:63-74.
16. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerace caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptde receptor knckout mice. Proc Natl Acad Sci USA 1999;96:14843-14847.
17. Aulinger B, D'alessio D. Glucagon like peptide 1: continued advanced, new target and espanding promise as a model therapeutic. Curr Opin Endocrinol Diabetes Obes 2007;14:68-73.
18. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutritients. Digestion 1995;56:117-126.
19. Balks HJ, Holst JJ, Von zur Muhlen A, Brabant G. Rapid oscillation in plasma glucagon-like peptide-1 (GLP-1) i humans: cholinergic control of GLP-1 secretion via muscarinic recptors. J Clin Endocrinol Metab 1997;82:786-790.
20. Rocca AS, Brubaker PL. Role of the vagus Nerve in Mediating Proximal Nutricient-induced Glucagon-Like peptide-1 secretion. Endocrinology 1999;140:1687-1694.
21. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on ppetite, gastric emptying, Energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;25:781-792.
22. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non -insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
23. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetics patients. J Clin Endocrinol Metab 2001;86:3717-3723.
24. Strader AP, Vahl TP, Jandacek RJ, Woods SC, d'Alessio D, Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005;288:E447-453.
25. Patriti A, Facchiano E, Annetti C, et al. Early Improvment of glucose Tolerance after ileal transposition in non- obese type 2 diabetes rat model. Obes Surg 2005;15:1258-1264.
26. Patriti A, Aisa MC, Annetti C, et al. How the hingut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expresion and L-cell number. Surgery 2007;142:74-85.
27. Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 2007;194:221-224.
28. Suzuki S, Ramos JB, Gomcalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit after Roux-en- Y gastric bypass in rat model. Surgery 2005;138:283-290.
29. Borg CM, le Roux CW, Gathei A, Bloom SR, patel AG. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP1, GLP2, and PYY levels. Obes Surg 2007;17:1193-1198.
30. Rubino F, Gagner M, gentileschi P, et al. The early efect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236-242.
31. Valverde I, Puente J, Martin-Duce A, et al. Changes in glucagon-like peptide-1 (GLP 1) secretion after biliopancreatic diversion or vertical banded gstroplasty in obese subjects. Obes Surg 2005;15:387-397.
32. Le Roux CW, Welbourn R, Werling M, et al. Gut Hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-785.
33. Le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108-114.
34. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like-peptide-1 and blunted glucose dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597-201.
35. Korner J, Inabnet W, Conwell I, et al. Differential effects of gastric bypass and banding on circulating gut hormone amd leptin level. Obesity 2006;14:1553-1561.
36. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are Markedly enhanced 1 month after Roux en Y gastric bypass surgery in obese patients with tyoe 2 diabetes. Diabetes Care 2007;30:1709-1716.
37. Ballantyne GH, Gumbs AA, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis : role of the adipocytokines, leptin, adiponrctin and resistin. Obes Surg 2005;15:692-699.
38. Tene Perez CE, Revilla-Monsalve MC, Amato D, et al. Correlation between serum leptin levels and insulin sensitivity in diffuse toxic goiter. Endocr Res 2004;30:19-27.
39. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Buophys Res Commun 1996;224:522-527.
40. Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF. Leptin suppression of insulin secretio by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997;46:1087-1093.
41. Rubino F, Marescaux J. Effect of duodenal-jejunal Exclusion in a non-obese anaimal model of type 2 diabetes. A new perpsective for an old disease. Ann Surg 2004;239:1-11.
42. Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003;88:3177-3183.
43. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocye protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in Rhesus monkeys. Diabetes 2001;50:1126-1133.
44. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectimia in obesity and type 2 diabetes: close associatio with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
45. Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese asians. Obes Surg 2002;10:1104-1110.
46. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponecti concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
47. Whiston BA, Leslie DB, Kellogg TA, et al. Adipokine response in diabetics and non diabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res 2007;142:295-300.
48. Faraj M, havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, leptin, and ghrelin before and after weight loss induced by gastric bypass in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594-1602.
49. Couce ME, Cottam D, Esplen J, Schauer PR, Burguera B. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg 2006;16:870-878.
50. Gumbs AA, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 2005;15:462-473.